Skip to main content Skip to search
""

M.S. in Biotechnology Management and Entrepreneurship

Making the World Smarter, Safer and Healthier

""

Eligible for

STEM-OPT
""
""

Affordable

$25k
Fixed-Rate Tuition
""
""

U.S. News & World Report

Top 100
University in the U.S.
""
""

Alumni Career Outcomes

95%
employed within 6 months
""

The M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Program Highlights

Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics

Lead product, program and project management across the biotechnology ecosystem

Career support and professional networking opportunities

Gain industry experience through internships and research

STEM-OPT eligible

Full Program Breakdown

The M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Program Highlights

Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics

Lead product, program and project management across the biotechnology ecosystem

Career support and professional networking opportunities

Gain industry experience through internships and research

STEM-OPT eligible

Swipe to learn more!

The M.S. in Biotechnology Management and Entrepreneurship is an interdisciplinary program designed specifically for the workforce needs of the biotechnology industry. This highly competitive program impacts society in the areas of food, fuel and health. In this program, you'll master the mission-critical scientific, technical and business knowledge needed to launch, manage, scale and commercialize biotechnology innovations and delivery systems. You’ll learn what it takes to shepherd a great idea through regulations, clinical trials, compliance and patents. And you'll merge your knowledge of science, technology and business, such as marketing, customer development, analytics and new business development, to effectively bring pharma and biotech products to market. 

From developing vaccines for infectious diseases, such as COVID-19, to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people. And the industry is booming. Startups, large-multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with the M.S. in Biotechnology Management and Entrepreneurship.

Master biotechnology foundations, including life sciences, biologics, biostatistics and clinical trials

Gain business and entrepreneurship skills, such as new business development, marketing, finance for startups and business analytics

Lead product, program and project management across the biotechnology ecosystem

Career support and professional networking opportunities

Gain industry experience through internships and research

STEM-OPT eligible

Research

Design and conduct company-sponsored research on topics currently impacting the pharmaceutical and biotech industries or work alongside faculty in university labs.

Current Projects

  • Assessment of market size, competitive landscape and impact of Einstein-Montefiore Biotechnology Accelerated Research Center (EMBARC) — Company Sponsor: Albert Einstein College of Medicine
  • Comprehensive startup market research to determine product market fit and investor profiles — Company Sponsor: BioVenture eLab at Weill Cornell Medicine
  • Risk assessment and de-risking strategy for a new class of antibody drug conjugate for treatment of solid tumors — Company Sponsor: GritBio
  • Etiology, treatment landscape, and patent search for A Gabapentin-Dextromethorphan-Quinidine combination product for treatment of chronic pain — Company Sponsor: BIOGVIR
  • Commercialization plan for a novel toothpaste-based approach to treating peanut allergies — Company Sponsor: Introimmune Therapeutics

Biotech Management Fellows

Join students and alumni from over 30 countries to work on pioneering research, citywide initiatives, and new technologies that help to make the world smarter, safer and healthier.

Benefits

  • Total tuition of $25k for your entire degree
  • Receive industry mentorship
  • Showcase your capstone at our annual conference
  • Publish your capstone in our conference proceedings

Take the guesswork out of paying for graduate school. You’ll pay a fixed rate tuition of $25k from start to finish, whether you finish in one or two years, or are a domestic or international student.

B.A./M.S. Pathways Option

Through the B.A./M.S. program, undergraduates from Yeshiva College and Stern College for Women can take up to nine graduate credits that count toward both the bachelor’s and master's degrees. After completing the bachelor’s, students can finish the graduate degree in just one more year. 

  • Admissions criteria: A minimum of 84 credits completed in any YC/SCW undergraduate major with a minimum GPA of 3.0 and a minimum grade of B in the prerequisite coursework listed below. Students can begin taking graduate courses in their senior year.
  • Prerequisites for graduate coursework: Biology Principles I and II with a minimum grade of B-plus (or equivalent AP or transfer credit).

For more information, visit www.yu.edu/pathways

Internships and STEM-OPT

Gain industry experience in major companies, startups and the YU Innovation Lab through internships that count toward your degree. The Master’s in Biotechnology Management and Entrepreneurship is a STEM-approved degree. International students may be eligible for up to 36 months of Optional Practical Training (OPT). The program also offers several opportunities for Curricular Practical Training (CPT). 

Recent Internships 

  • Merck
  • Kantar Health 
  • BioMarin 
  • Marwood Group 
  • New York Stem Cell Foundation 
  • Lucerna 
  • SFA Therapeutics 

Interested in this program? Apply Now! 

At a Glance

36-credit Master of Science

Full-time or part-time

Online or on-campus in New York City

Evening courses so that you can work full-time while completing your degree

Leading industry expert faculty

Small classes where you’ll get to know everyone by name

Helpful Links

Webinars

Join Our Community

Contact Us

Jared Hakimi 
Director of Graduate Admissions
jared.hakimi@yu.edu
646-592-4722
Schedule an Appointment 

Shayna Matzner
Assistant Director of Graduate Admissions
shayna.matzner@yu.edu
646-592-4726
Schedule an Appointment

Xavier Velasquez
Assistant Director of Graduate Admissions
xavier.velasquez@yu.edu
646-592-4737
Schedule an Appointment

Admissions Criteria 

Candidates must possess a bachelor’s degree from an accredited college or university. TOEFL or IELTS scores demonstrating strong communication skills are required for candidates whose bachelor's degrees were earned at a non-English-speaking institution. We also offer a fully online, 11-week intensive English program for applicants with low- to upper-intermediate English reading, speaking and writing skills. 

Contact an admissions director for more information. 

Application Requirements 

Applicants must submit the following:  

  • Online application  
  • Official transcripts from all colleges or universities attended 
  • Personal statement detailing your career goals and interest in the program 
  • TOEFL, IELTS or Duolingo scores (for candidates whose bachelor's degrees were earned at a non-English-speaking institution) 
  • $50 application fee

Application Deadlines 

For up-to-date application deadlines, visit Graduate Admissions.

Tuition, Financial Aid, & Scholarships 

The Office of Student Finance maintains current tuition and fees for all graduate programs. 

Scholarships

All applicants are automatically considered for scholarships. You do not need to submit any additional information. Scholarship awards are determined during the application review process. 

Questions? 

Schedule an appointment with an admissions director if you have questions about your qualifications, financial aid opportunities and financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.

Learn More

Helpful Links

Webinars

Join Our Community

Contact Us

Jared Hakimi 
Director of Graduate Admissions
jared.hakimi@yu.edu
646-592-4722
Schedule an Appointment 

Shayna Matzner
Assistant Director of Graduate Admissions
shayna.matzner@yu.edu
646-592-4726
Schedule an Appointment

Xavier Velasquez
Assistant Director of Graduate Admissions
xavier.velasquez@yu.edu
646-592-4737
Schedule an Appointment

Admissions & Financial Aid

Admissions Criteria 

Candidates must possess a bachelor’s degree from an accredited college or university. TOEFL or IELTS scores demonstrating strong communication skills are required for candidates whose bachelor's degrees were earned at a non-English-speaking institution. We also offer a fully online, 11-week intensive English program for applicants with low- to upper-intermediate English reading, speaking and writing skills. 

Contact an admissions director for more information. 

Application Requirements 

Applicants must submit the following:  

  • Online application  
  • Official transcripts from all colleges or universities attended 
  • Personal statement detailing your career goals and interest in the program 
  • TOEFL, IELTS or Duolingo scores (for candidates whose bachelor's degrees were earned at a non-English-speaking institution) 
  • $50 application fee

Application Deadlines 

For up-to-date application deadlines, visit Graduate Admissions.

Tuition, Financial Aid, & Scholarships 

The Office of Student Finance maintains current tuition and fees for all graduate programs. 

Scholarships

All applicants are automatically considered for scholarships. You do not need to submit any additional information. Scholarship awards are determined during the application review process. 

Questions? 

Schedule an appointment with an admissions director if you have questions about your qualifications, financial aid opportunities and financing your graduate degree. We can do a preliminary transcript review and discuss your admissions and financing options with the Katz School.

Program News

peptides

Market Analysis Finds Commercial Promise for Cancer Drug

Read more about the research

Market Analysis Finds Commercial Promise for Cancer Drug

Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. 

The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. 

In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. 

He found that colorectal cancer patients would be a prime population for Sapience’s novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. “Colorectal cancer presents the highest upside according to the revenue projection model,” said Strauss, who is a healthcare consultant for the Marwood Group, “and presents the largest potential available population among the five cancer types studied.” 

Sapience’s therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system’s response to cancerous tumors. The interactions targeted by Sapience are considered “undruggable” due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. 

“Peptides combine the best properties of small and large molecules,” said Dr. Kappel, “and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.” 

Robert Friedman, an adjunct professor in the biotechnology program and Strauss’s advisor, said that Strauss’s presentation demonstrates the strength of the “molecule-to-market nature” of the Katz School’s biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. 

“Avi’s understanding of the science, clinical development and the market were all critical to successfully completing the project,” he said. “The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.”

""

New York City a Hub for Biotech Innovation

Read more about the city's $500 million investment

New York City a Hub for Biotech Innovation

Four of the top 10 biopharma clusters are located in the New York area. New York City’s Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. 

From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people.  

Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master’s in biotechnology management and entrepreneurship. 

Josh Lankin

Analyzing the Potential for a Startup’s Drugs

Read more about Josh Lankin’s work

Analyzing the Potential for a Startup’s Drugs

Pennsylvania-based biopharmaceutical startup, SFA Therapeutics, brought in Biotech student to analyze the company’s efforts in developing breakthrough drugs. 

Drug development is a risky endeavor, especially for a startup company. It requires large capital expenditures, waiting out long timelines and overcoming regulatory hurdles to bring a drug to market. Prioritizing and valuing which drugs to develop can make or break a company. 

That’s why the Pennsylvania-based biopharmaceutical startup, SFA Therapeutics, brought in Josh Lankin when he was a student last year in the Katz School’s Biotechnology Management and Entrepreneurship program to conduct an analysis of its efforts in developing breakthrough drugs for a variety of ailments. 

“Josh did a great job on an interesting project,” said Dr. Ira Spector, CEO of SFA Therapeutics and a former drug developer with Wyeth, Pfizer, Allergan and ICON. 

SFA Therapeutics is developing and commercializing drugs, he said, that have broad implications for the treatment of inflammatory diseases. The company is working on treatments for Hepatitis B, liver cancer, Pemphigus which causes blisters, psoriasis, and Uveitis, a form of eye inflammation. 

“We think we have a fundamental technology that applies to a broad range of diseases,” said Dr. Spector. 

Dr. Rana Khan, director of the Biotechnology Management and Entrepreneurship program, said she created a partnership between Yeshiva University and the biotechnology industry to give students experience and to demonstrate the value of a Katz degree. Katz students earn credit by working on projects for companies, like SFA Therapeutics, as part of their final capstone course. 

“The master’s program is a unique blend of science, management and entrepreneurship, and it gives our students the tools to sharpen their scientific knowledge and the opportunity to manage and create their own biotech companies,” she said. 

Dr. Spector said he asked Lankin, who is now an associate consultant in Oncology and Specialty Therapeutics with Kantar Health, to use SFA Therapeutics’ “mechanism of action” to rank several diseases in order of priority for potential commercialization before his company goes to venture capitalists to ask for development funding. Lankin developed the methodology for ranking the potential diseases where the mechanism could be applied. 

“Having a validated methodological approach to explain our choices and what our roadmap would look like was the purpose of Josh’s assignment,” he said. “He helped validate that our strategy is sound and that the diseases we’ve chosen make sense.” 

The roadmap articulates a strategy for drug development given a host of factors, such as the competitive landscape, unmet medical need, potential value, market size, scientific potential, and time it would take to bring a drug to market. From a development strategy perspective, Lankin created filters to assess the merits of each of these potential indicators and a color-coded matrix that evaluated each criterion. 

An oral drug for psoriasis, his analysis revealed, has the potential to be the most profitable for SFA Therapeutics. Psoriasis affects 120 million patients worldwide, or 2 to 3 percent of the total population, including 8 million Americans. 

“That matrix of criteria he created for the roadmap showed that, yes, the development of psoriasis drugs made the best use of the company’s resources,” said Dr. Spector.

Yeshiva University shield

YU Ranked 68th in Best National Universities

Read more about YU’s rankings

YU Ranked 68th in Best National Universities

Yeshiva University ranks 68th among National Universities and 33rd in Best Value Schools in the 2022 edition of U.S. News & World Report’s Best Colleges.

Read more about Yeshiva University's rankings in U.S. News & World Report.

peptides

Market Analysis Finds Commercial Promise for Cancer Drug

Read more about the research

Market Analysis Finds Commercial Promise for Cancer Drug

Avi Strauss, a recent Katz School biotech graduate, has performed a detailed market analysis on a new drug therapy for colorectal cancer. 

The analysis recommended that Sapience Therapeutics, a New York-based biotech company, develop a molecule called a novel beta-catenin antagonist for treatment of the cancer. Beta-catenin is part of the Wnt signaling pathway, which promotes tumor growth and suppresses the immune system. 

In addition to colorectal cancer, Strauss reviewed four other types of cancer that have high mortality rates and resist conventional therapies: acute lymphocytic leukemia, breast cancer, melanoma, and multiple myeloma. 

He found that colorectal cancer patients would be a prime population for Sapience’s novel peptide because of the high incidence of a mutation in the Wnt signaling pathway that results in its overactivation and leads to the formation of cancer. “Colorectal cancer presents the highest upside according to the revenue projection model,” said Strauss, who is a healthcare consultant for the Marwood Group, “and presents the largest potential available population among the five cancer types studied.” 

Sapience’s therapeutic approach, according to Dr. Kappel, is to target protein-protein interactions (PPIs) that seem necessary to the survival of cancer or that inhibit the immune system’s response to cancerous tumors. The interactions targeted by Sapience are considered “undruggable” due to the intracellular location of the PPIs, making them difficult to treat with small-molecule drugs such as chemotherapies that are incapable of disrupting PPIs, and biologic-based drugs like monoclonal antibodies that are too big to enter cells. 

“Peptides combine the best properties of small and large molecules,” said Dr. Kappel, “and present an opportunity to disrupt intracellular PPIs and to reduce mortality in cancer patients and possibly in other diseases.” 

Robert Friedman, an adjunct professor in the biotechnology program and Strauss’s advisor, said that Strauss’s presentation demonstrates the strength of the “molecule-to-market nature” of the Katz School’s biotechnology program and its emphasis on understanding the science, and translating it into practical and actionable decisions. 

“Avi’s understanding of the science, clinical development and the market were all critical to successfully completing the project,” he said. “The piece de resistance of his elegant work is undoubtedly the market forecast model that the client will incorporate in its corporate planning process for years to come.”

""

New York City a Hub for Biotech Innovation

Read more about the city's $500 million investment

New York City a Hub for Biotech Innovation

Four of the top 10 biopharma clusters are located in the New York area. New York City’s Economic Development Corporation has started investing $500 million into LifeSciNYC, an initiative enshrining New York as a global leader in life sciences innovation and R&D. The initiative is also attracting entrepreneurs from around the world who have started 4,000 companies. 

From deploying therapeutic glycoproteins to treat autoimmune diseases to commercializing CRISPR-edited genetic material for pesticide-resistant crops, biotech entrepreneurs are improving global health conditions and the quality of life for millions of people.  

Startups, large multinational companies and leading medical and research facilities are seeking managers of new products, projects, business development, regulatory and compliance, and clinical trials. Secure your place in this fast-growing, high-paying job market with a master’s in biotechnology management and entrepreneurship. 

Josh Lankin

Analyzing the Potential for a Startup’s Drugs

Read more about Josh Lankin’s work

Analyzing the Potential for a Startup’s Drugs

Pennsylvania-based biopharmaceutical startup, SFA Therapeutics, brought in Biotech student to analyze the company’s efforts in developing breakthrough drugs. 

Drug development is a risky endeavor, especially for a startup company. It requires large capital expenditures, waiting out long timelines and overcoming regulatory hurdles to bring a drug to market. Prioritizing and valuing which drugs to develop can make or break a company. 

That’s why the Pennsylvania-based biopharmaceutical startup, SFA Therapeutics, brought in Josh Lankin when he was a student last year in the Katz School’s Biotechnology Management and Entrepreneurship program to conduct an analysis of its efforts in developing breakthrough drugs for a variety of ailments. 

“Josh did a great job on an interesting project,” said Dr. Ira Spector, CEO of SFA Therapeutics and a former drug developer with Wyeth, Pfizer, Allergan and ICON. 

SFA Therapeutics is developing and commercializing drugs, he said, that have broad implications for the treatment of inflammatory diseases. The company is working on treatments for Hepatitis B, liver cancer, Pemphigus which causes blisters, psoriasis, and Uveitis, a form of eye inflammation. 

“We think we have a fundamental technology that applies to a broad range of diseases,” said Dr. Spector. 

Dr. Rana Khan, director of the Biotechnology Management and Entrepreneurship program, said she created a partnership between Yeshiva University and the biotechnology industry to give students experience and to demonstrate the value of a Katz degree. Katz students earn credit by working on projects for companies, like SFA Therapeutics, as part of their final capstone course. 

“The master’s program is a unique blend of science, management and entrepreneurship, and it gives our students the tools to sharpen their scientific knowledge and the opportunity to manage and create their own biotech companies,” she said. 

Dr. Spector said he asked Lankin, who is now an associate consultant in Oncology and Specialty Therapeutics with Kantar Health, to use SFA Therapeutics’ “mechanism of action” to rank several diseases in order of priority for potential commercialization before his company goes to venture capitalists to ask for development funding. Lankin developed the methodology for ranking the potential diseases where the mechanism could be applied. 

“Having a validated methodological approach to explain our choices and what our roadmap would look like was the purpose of Josh’s assignment,” he said. “He helped validate that our strategy is sound and that the diseases we’ve chosen make sense.” 

The roadmap articulates a strategy for drug development given a host of factors, such as the competitive landscape, unmet medical need, potential value, market size, scientific potential, and time it would take to bring a drug to market. From a development strategy perspective, Lankin created filters to assess the merits of each of these potential indicators and a color-coded matrix that evaluated each criterion. 

An oral drug for psoriasis, his analysis revealed, has the potential to be the most profitable for SFA Therapeutics. Psoriasis affects 120 million patients worldwide, or 2 to 3 percent of the total population, including 8 million Americans. 

“That matrix of criteria he created for the roadmap showed that, yes, the development of psoriasis drugs made the best use of the company’s resources,” said Dr. Spector.

Yeshiva University shield

YU Ranked 68th in Best National Universities

Read more about YU’s rankings

YU Ranked 68th in Best National Universities

Yeshiva University ranks 68th among National Universities and 33rd in Best Value Schools in the 2022 edition of U.S. News & World Report’s Best Colleges.

Read more about Yeshiva University's rankings in U.S. News & World Report.

Skip past mobile menu to footer